Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up ...

Corcept Therapeutics Incorporated CORT recently announced the submission of a new drug application (NDA) to the FDA for its ...

radiotherapy or drug therapy. While medical therapy for Cushing's syndrome has been limited, several new agents are being investigated. This aim of this review is to analyze and present the ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The drug has received orphan drug designation in the United States and the European Union for the treatment of Cushing's syndrome. Cushing's syndrome is a condition characterized by excessive ...

Korlym became the first drug approved by the FDA to treat Cushing syndrome in 2012. It wasn’t until recently, however, that researchers discovered that hypercortisolism, previously believed to ...

Also Read: Corcept Therapeutics’ Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast CATALYST is a prospective Phase 4 study with two parts.

Concomitant medication can contribute to the diagnostic inaccuracy of the combined dexamethasone–corticotropin-releasing hormone (CRH) test in Cushing syndrome. The ability to differentiate ...

This medication is teratogenic and is not currently approved for use in the treatment of Cushing's syndrome. [51] ACTH: Adrenocorticotrophic hormone; b.i.d.: Twice daily; GI: Gastrointestinal ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the ...